Navigation Links
Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development
Date:4/21/2008

Reagent-Free Preparative Transfection Eliminates the Need to Engineer Stable Cell Lines and Enables the use of Primary Cells for Cell Based Assays and Screening

GAITHERSBURG, Md., April 21 /PRNewswire-USNewswire/ -- MaxCyte announces today the introduction of its ITF Inline Transfection System, a validated platform for preparative transfection, based on unique flow electroporation technology. This system enables rapid and efficient transfection of any kind of cell or cell line with any molecule (plasmids, proteins, protein complexes, drugs, mRNA, siRNA), at scales ranging from micro-liters to liter volumes.

MaxCyte's ITF Inline Transfection System enables transient transfection of cell lines as well as primary cells, and is now available for drug discovery and screening applications. The sterile, closed system provides unparalleled consistency, scalability, and loading efficiency while avoiding the inherent drawbacks of alternative methods.

Many cell based assays and research projects are based on recombinant cell lines. Optimizing such cell lines so they express a desired set of properties and are compatible with a particular screening platform takes considerable time and expense. Because of its ease and speed, transient transfection is increasingly used to replace cloning and recombinant work in a wide range of applications (e.g. ion channel based drug or GPCR screening). The cost-effective MaxCyte ITF Inline Transfection system replaces current preparative transfection technologies which depend on expensive and complicated virus constructs, lipid based transfection agents, or small scale electroporation devices.

The high efficiency and viability of cells processed by the MaxCyte ITF Inline Transfection System make it possible to focus on biologically relevant cell lines, and even primary cells. Inline transfection is also fully scalable. It can be used to transfect 10^5 - 10^7 cells in seconds and up to 10^10 cells in less than 30 minutes. Viability is routinely greater than 90%, with more than 90% cell loading and transfection efficiency for many cell lines. Protocols are available for a wide range of cell lines and primary cells.

About MaxCyte

The MaxCyte transfection platform was first designed, developed, and commercialized for cell-based therapies and is currently used in human therapeutic applications. This technology is now available for research purposes under a limited label license.

The Company's proprietary, non-viral, ex vivo cell loading technology provides safety, scalability and reproducibility fundamental to commercializing successful cell-based therapies. MaxCyte has demonstrated the value of its versatile technology in partnered therapeutic programs in oncology, pulmonary, metabolic and infectious diseases as well as in development collaborations with leading researchers. Current clinical programs with MaxCyte-engineered cells include: a Phase IIa clinical study for treatment of chronic lymphocytic leukemia (CLL) and a Phase IIa study using engineered progenitor cells for the treatment of primary Pulmonary Arterial Hypertension (PAH). MaxCyte has recently partnered with Medinet (JP) to commercialize a cell based therapy to be launched in 2008. In addition, there are advanced preclinical programs in oncology and regenerative medicine with more than 16 commercial and academic partners currently using the MaxCyte technology. The MaxCyte system has an FDA Master File in place at the Center for Biologics Evaluation and Research (CBER).

For more information, visit http://www.maxcyte.com/cell-based-screening.shtml


'/>"/>
SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
2. Stem Cell Research Provides Medical Breakthrough to Repair Heart Cell Damage Created by a Heart Attack
3. Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
4. AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
5. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
6. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
7. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
8. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Microwave Treatments for Enlarged Prostate Cause Blood Pressure Surges
11. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... YORK , December 2, 2016 ... Braces & Support) is Expected to Gain a Significant Market ... to Orthopedic Ailments  ... , According to ... Study on Medical Implants Sterile Packaging: Clamshell Product Type Segment ...
(Date:12/2/2016)... On Thursday, the NASDAQ Composite and ... the Dow Jones Industrial Average managed to stay in green. ... which prompted Stock-callers this morning to look at the performances ... NUVA ), Smith & Nephew PLC (NYSE: SNN ... Cesca Therapeutics Inc. (NASDAQ: KOOL ). You can ...
(Date:12/2/2016)... -- The concept of rare diseases and the idea that ... has been taking shape in Europe ... initiatives related to orphan medicinal products have been emerging at ... states individually. Many member states in the EU have led ... medicinal products, the result of which took the shape of ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change Medicare health ... is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their ... D) need to make changes during this period order for their new policy to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... More than ... and while 84 percent of parents report speaking with their child about sex related ... sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its second ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 ... unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to ... been available in several ShopRite and FoodTown stores in NJ and received rave comments ...
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... they now offer a comprehensive in-house dental plan for all patients. Understanding that ... a plan that gives patients a number of perks, including discounts on many ...
Breaking Medicine News(10 mins):